Dr. Jeremy A. Falk, MD

Dr. Falk practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Falk's NPI, 1114953890, was assigned on June 24, 2006. Dr. Falk graduated from Ohio State College of Medicine in 1998. Dr. Falk holds California license A90299.

Dr. Falk's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Falk's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Falk to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Falk practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Falk's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Falk is board certified in sleep medicine by the ABSM. Dmand AI has Dr. Falk's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists asthma, chronic lung disease, chronic obstructive pulmonary disease (COPD), pleural effusion, pneumonia, pulmonary fibrosis and tobacco use among the conditions Dr. Falk treats.

CMS data shows 423 Medicare services from Dr. Falk across 9 procedure codes in 2024, for 181 Medicare patients. Medicare paid $36,351 for them.

CMS counts 181 Medicare patients who saw Dr. Falk in 2024. The largest group is 65 to 74, with 88 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 3.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Falk's median patient age at 66, with 49% women.

In 2024, Dr. Falk wrote 729 Medicare Part D claims for 72 patients. 80% of them were for generic drugs. CMS names the drug for 508 of them, across 14 drugs with 11 or more claims each, at $203,783 in total drug cost. In 2023, CMS named 431 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Falk for performance year 2024, reported as part of a group. Dr. Falk accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Falk as offering telehealth.

Dmand AI links 12 papers to Dr. Falk, published from 2007 to 2025. 2007 was the busiest year, with 2. The most frequent topics are Pneumonectomy and Pulmonary Emphysema. Dr. Falk's most frequent co-authors are Robert William Hallowell, MD, Rohit Aggarwal, MD and Akbarshakh Akhmerov, MD.

Dmand AI links Dr. Falk to 2 clinical trials. Conditions studied include alpha 1-Antitrypsin Deficiency, Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis.

CMS Open Payments shows 11 general payments to Dr. Falk from 7 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $2,477.

Dr. Falk graduated from Ohio State College of Medicine in 1998.

Dr. Falk is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.